Cipla: The Pharma Company That Sold an AIDS Drug for a Dollar a Day and Changed Global Healthcare

Some brands build their reputation through advertising. Cipla built its through a single, defiant act of pricing, offering a life-saving drug to some of the world's poorest patients for less than the cost of a cup of coffee, and in doing so, forced the entire global pharmaceutical industry to answer a question it had spent decades avoiding.

A Chemist Who Chose Rebellion Over a Law Career

Khwaja Abdul Hamied was born on October 31, 1898, in Aligarh, in British India. As a teenager, he witnessed an act of colonial high-handedness that lit a spark of nationalism in him, one that, by most accounts, never really went out. He studied at Muir Central College and the University of Allahabad, where chemistry became less an academic interest and more a tool for something bigger. In the early 1920s, he met Mahatma Gandhi and went on to co-found Jamia Millia Islamia in New Delhi alongside Zakir Husain.

In 1924, his family sent him to study in England. Midway through the journey, Hamied changed ships and headed to Germany instead, then the world's leading centre for chemistry. There, he earned his doctorate, and met and married a Lithuanian Jewish socialist he encountered on a Berlin lake. As the Nazi party rose to power, the couple fled Germany and returned to India.

Founding a Company on a Single Conviction

On August 17, 1935, in Bombay, Hamied founded the Chemical, Industrial and Pharmaceutical Laboratories, opening its doors to the market with its first products in September 1937. The company's founding was deeply tied to India's Swadeshi movement and Gandhi's ideals of self-sufficiency, Hamied envisioned an India that no longer needed to depend on foreign pharmaceutical companies, and one where quality medicine was genuinely accessible to ordinary, often desperately poor, Indians. In a remarkable early gesture, Hamied transferred all of his own patents and proprietary formulas to the company without seeking any royalties for himself.

Gandhi personally visited the company in 1939, recognising its growing importance just as the British government began turning to it for wartime medicine supplies. During the Second World War, the company became the largest supplier of quinine and Vitamin B12 to Allied soldiers, a genuine mark of the operational capability it had built in just a few short years.

Passing Down a Mission, Not Just a Company

Khwaja Abdul Hamied passed away in 1972. His son, Yusuf Hamied, a Cambridge-trained chemist, took over and led the company for the next 52 years. Before handing over control, the father reportedly told his son plainly that, unlike other pharmaceutical companies around the world, their company existed not to chase profit, but to bring relief and healthcare to the poor who might otherwise die for want of quality medicine. In July 1984, the company's name was officially shortened to Cipla.

Under Yusuf Hamied, Cipla's scientific ambitions grew substantially. In 1991, the company partnered with the Indian Institute of Chemical Technology on a breakthrough in cancer chemotherapy, and in 1995, Cipla developed Deferiprone, the world's first oral iron chelator.

Standing Up to Both a Government and an Industry

Cipla's willingness to manufacture generic versions of patented drugs eventually drew international attention, including a formal complaint from the United States government over alleged patent violations. When the matter reached Prime Minister Indira Gandhi, she reportedly stood by the company rather than caving to pressure, after Yusuf Hamied personally explained the founding mission behind Cipla's work, bringing affordable, quality medicine to people who otherwise couldn't afford it.

That conviction reached its most consequential moment in the early 2000s. As the HIV/AIDS epidemic devastated Sub-Saharan Africa, Western pharmaceutical companies were selling antiretroviral treatments at prices running into thousands of dollars per patient per year, effectively putting life-saving treatment entirely out of reach for the vast majority of people who needed it. Yusuf Hamied and Cipla made global headlines by offering a combined, triple-therapy antiretroviral drug to Médecins Sans Frontières, and by extension to patients across Africa, for under a dollar a day. The move directly challenged the global pharmaceutical industry's pricing practices and became a landmark moment in the worldwide debate over access to essential medicine, widely credited with helping pressure major international drug makers to significantly lower their own HIV treatment prices in the years that followed.

A Company Still Guided by Its Founding Promise

Cipla has continued producing widely used medications in the decades since, including hydroxychloroquine, used for malaria, lupus, and rheumatoid arthritis. Today, the company operates as a major global pharmaceutical player, headquartered in Mumbai, led by Chairperson Y.K. Hamied and CEO Umang Vohra, with reported revenue of ₹27,548 crore in its 2025 financial year and roughly 27,764 employees as of March 2024. Leadership continuity within the Hamied family has continued as well, with the company's mission now carried forward into a third generation.

The Marketing Strategy: Let a Single Act of Conscience Become the Brand Itself

What makes Cipla genuinely remarkable as a brand case study is that its most powerful global reputation-building moment wasn't an advertising campaign at all, it was a pricing decision. By offering its AIDS drug at under a dollar a day, Cipla generated an extraordinary wave of international media coverage and public goodwill, positioning the company globally as, in the words widely used to describe it, "the drugmaker with a conscience," without spending a single rupee on traditional promotion. That single act did more for Cipla's international brand credibility than decades of conventional marketing could have achieved.

This wasn't an isolated marketing stunt either, it was the direct, structural continuation of a founding philosophy embedded into the company from 1935 onward, reinforced by a founder who gave away his own patents for free, and passed down deliberately from father to son as the company's core, unchanging identity. In an industry where trust is notoriously difficult to build through advertising alone, Cipla's approach shows that sometimes the most effective brand strategy a company can adopt is simply proving, through costly, real-world action, that it actually believes what it claims to stand for.

Ninety Years of Keeping One Promise

Cipla's story, from a chemist's youthful act of rebellion against colonial rule to a company that reshaped how the world thinks about access to life-saving medicine, is ultimately about a single conviction carried faithfully across three generations. A promise made quietly to Gandhi in 1939 was kept by a founder, handed down to his son, and kept again, most visibly, in the price of a single pill offered to people who had almost nothing left to lose.